Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Clin Lipidol. 2016 Mar 8;10(4):808–815. doi: 10.1016/j.jacl.2016.03.001

Figure 2. Distribution of the relative abundance of apoA-II oxidized monomer and total oxidized apoA-II in diabetes versus control samples.

Figure 2

The ratio of apoA-II Mox/M was significantly increased in participants with diabetes (n=30) compared to participants without diabetes (n=25). The differences persisted after adjusting for HDL cholesterol levels and BMI (p=0.003). The total oxidation ratio computed for all proteoforms was also higher in participants with diabetes (p=0.005) M: apoA-II monomer. Mox: apoA-II monomer oxidized (+16). *p<0.01